

OPINION

Open Access

Sixty years trying to define the malaria burden in Africa: have we made any progress?

Robert W Snow^{1,2}

Abstract

Controversy surrounds the precise numbers of malaria deaths and clinical episodes in Africa. This would not have surprised malariologists working in Africa 60 years ago as they began to unravel the enigma that is 'malaria'. Malaria is a complex disease manifesting as a multitude of symptoms, degrees of severity and indirect morbid consequences. Clinical immunity develops quickly and the presence of infection cannot always be used to distinguish between malaria and other illnesses. During the 1950s and 1960s parasite prevalence was used in preference to statistics on malaria mortality and morbidity. An argument is made for a resurrection of this measure of the quantity of malaria across Africa as a more reliable means to understand the impact of control.

Keywords: Malaria mortality, Morbidity, Parasitemia, Measurement, Monitoring, Africa

The first estimates of *Plasmodium falciparum* mortality in Africa

During a visit to Uganda and Kenya in 1929, SP James wrote '*... there is, as yet, little or no knowledge even of the symptoms and effects of the chronic infestations with malaria parasites from which many native children and adults suffer, to say nothing of the wide gaps in knowledge of [sic] regarding the distribution, relative incidence and seasonal prevalence of different species of the malaria parasite*' [1].

Over the next 30 years, epidemiological studies improved our basic understanding of the clinical impact of malaria infection among communities living under stable, endemic settings in Nigeria [2-4], Liberia [5], Ghana [6,7], the Belgian Congo [8,9], Kenya [10,11] and Tanzania [12,13]. All these studies identified the power and rapidity of natural, repeat parasite exposure on the development of clinical immunity, the resultant absence of disease in adults and how immunity confounded any reliable estimations of the clinical burden posed by infection in rural communities in Africa.

In his comprehensive treatise on malaria, WF Boyd stated that '*...there is little value to reports received from physicians malaria morbidity reporting, even where malaria is classed as a reportable disease, is notoriously*

inadequate and unreliable, and nowhere as far as is known to us personally, is it sufficiently complete to be put to epidemiological use' [14]. According to those writing on their experiences, the consensus was that '*There is little doubt that the diagnosis of malaria in the immune or semi-immune African is subject as often as not to individual interpretation of clinical symptoms by the medical officer..... to complicate the issue, a positive blood-slide from the indigenous inhabitant of West Africa is not necessarily a criterion of the diagnosis*' [4].

Nevertheless, there was pressure to articulate the malaria burden in Africa as part of the World Health Organization's Global Malaria Eradication Programme (GMEP). A review of autopsy findings in Lagos performed on 3,085 children younger than 15-years old between 1933 and 1948 [4], formed the basis upon which it was estimated that 5% of children born in Africa would die before their fifth birthday from malaria and, by extrapolation, led to approximately 1 million malaria deaths every year. The 'million malaria deaths' became an accepted prelude to any report on malaria in Africa for decades.

Renewed interest in clinical epidemiology of malaria and new numbers: 1990s

It took another forty years before an interest in the clinical epidemiology of *Plasmodium falciparum*, the most significant malaria parasite transmitted in Africa in terms of disease burden, was to re-emerge [15]. Studies

Correspondence: rsnow@kemri-wellcome.org

¹Spatial Health Metrics Group, Department of Public Health Research, KEMRI-Wellcome Trust Research Program, Nairobi, Kenya

²Centre for Tropical Medicine & Global Health, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, UK

using active surveillance for fever with infection, hospital-based detection of the phenotypes of severe malaria and community-based mortality surveillance increased across Africa generating a wealth of new information. New burden estimates began to emerge based on replications of single studies such as those done by Bruce-Chwatt in the 1950s [16,17].

Toward the end of the 1990s, Africa was in the grips of a malaria epidemic [18]. The need to raise the profile of malaria in Africa, as part of advocacy for an increase in financing for the nascent Roll Back Malaria initiative [19], demanded new numbers. At the same time novel approaches to estimating global cause-specific mortality and disability burdens were gaining credibility for setting international health priorities [20]. In 1999, combinations of data were used to provide a new estimate of the malaria mortality burden in Africa based on assemblies of survey data on clinical attack rates and verbal autopsy or confirmed malaria death rates [21]. This analysis estimated there were more than 221 million febrile clinical events due to *P. falciparum*. Approximately one million deaths were directly attributable to malaria in 1995 [21], a similar finding to that of Bruce-Chwatt's nearly 50 years earlier. Since then adaptations of this approach have been championed by many (including the author), providing new, refined numbers through increasingly complex models and marginal increases in empirical epidemiological data [22-41].

Generating new numbers is at risk of becoming an industry, no longer informed by adequate biological, clinical and public health reflection or need. Do we really know how many clinical events or deaths are due to *P. falciparum* in Africa? More importantly, are we measuring a quantity that is malaria morbidity and mortality?

Why is it so difficult to measure the malaria burden in Africa?

Even with comparatively sophisticated surveillance, morbid and fatal events due to malaria in Africa are often treated outside formal health systems and cause of death largely unverifiable. Malaria is a complex disease manifesting as a multitude of symptoms, degrees of severity, with indirect morbid consequences. Without extensive laboratory testing, most symptoms of malaria are indistinguishable from other major causes of morbidity and mortality in young children. Clinical immunity develops quickly during early childhood following repeated parasite exposure, yet how many new infection encounters result in premunition against disease and why some children die and others survive remains unclear [15]. Because immunity develops throughout childhood, the presence of infection cannot always be used to distinguish between malaria and other illnesses sharing similar presenting symptoms.

Recent disease burden estimations have focused almost entirely on direct (those due to the defined clinical syndromes of malaria) measures of morbidity and mortality. For mortality the survey approaches assume that one can use a history from a bereaved relative, a verbal autopsy, to unambiguously assign a death to a single cause, malaria. This is a challenge for even the most experienced clinicians with a severely ill patient in front of them and supported by the best possible laboratory and diagnostic services. Not surprisingly, comparisons of verbal autopsy diagnoses made weeks or months after a child had died of confirmed malaria in hospital have all shown poor sensitivity across Africa [42]. Some have argued that, despite all its limitations, the verbal autopsy is the best tool we currently have [43], but it may be too blunt to provide any reliable data on deaths that are an immediate consequence of a single malaria episode.

Epidemiological models of morbidity do not recognize the intrinsic difficulties of measuring these events. Case definitions change with age and with endemicity [44-50], passive versus active case detection provides very different clinical endpoints [51] and repeat weekly examinations of the same individual alter the 'natural' incidence of disease [52]. Standardized clinical endpoints during randomized control trials of new interventions provide important efficacy data, but do not reflect a natural disease burden within trial sites or between sites across different transmission conditions in Africa.

Theory suggests that the association between malaria mortality and transmission intensity is non-linear [53]; the few data available on severe, life-threatening disease support the position of a non-linear association with transmission intensity that saturates at moderate levels of repeat parasite exposure [54,55]. In reality, without better measures of disease outcome, the precise relationship between mortality and malaria transmission remains unknown [56].

As part of recent efforts to define the *P. falciparum* global burden 25 estimates of epidemiologically measured incidence from 16 locations between 1993 and 2001 were used to interpolate risks across the African continent [30]; for mortality, results from 110 verbal autopsy studies from 64 locations and 11 'national' studies in nine African countries were used to provide estimates by year by country between 1980 and 2013 [37,41]. The paucity of empirical disease data in time and across the vast space occupied by diverse epidemiological, social and health system conditions is striking, providing a constant barrier to the generalizability of this approach to burden estimation.

Providing modelled uncertainty around point estimates of morbidity and mortality aims to provide statistical legitimacy for the interpolated burden numbers. The width of the confidence intervals either side of the median point

estimates are often numerically the same as the median estimate. Inevitably, the confidence intervals overlap between different modelled estimates, leading some to argue that newer modelling approaches are as 'good' as older modelling approaches [57]. A more honest interpretation is that we cannot be statistically confident in any modelled estimate of malaria morbidity or mortality in Africa.

There continues to be a failure to triangulate model predictions with other information on disease burden in Africa. The most recent malaria incidence and mortality models propose that there were more than 19,000 malaria cases and 164 malaria deaths in 2013 in Swaziland [41]. During a national sample survey of infection in 2010 only two infections (one *P. falciparum* and one *P. malariae*) were identified by polymerase chain reaction [58]; malaria is a notifiable disease and case investigations of 779 malaria events showed that only 404 cases over three years (2010 to 2012) were a result of locally acquired infections [59]. The Rwandan government, aiming for elimination, might be equally surprised by the estimated 3,569 deaths directly attributed to *P. falciparum* in 2013 [41]. These examples highlight a more general point: we need to evolve a culture of careful multiple data investigation, triangulation and interrogation as a check on modelling approaches to disease burden at global scales.

Indirect effects of parasitization

The standard global disease burden approach assumes that one child dies from one disease [20]; as such, significant indirect consequences of malaria infection are ignored. The consequences of reducing malaria parasite exposure on non-malaria mortality have been described during aggressive vector control across Africa. At Pare-Taveta, on the Kenyan-Tanzanian border, three years of house spraying reduced parasite rates from 60% to 5% and was associated with a halving of infant and under-five mortality that reverted to pre-intervention levels after spraying ceased [60,61]. Indoor house spraying with residual insecticides in a high transmission area of Kenya resulted in an almost immediate 96% reduction in parasite exposure that led within three years to a 44% reduction in crude death rates among all age groups and a 40% reduction in infant mortality [62]. Recently, eight rounds of house-spraying and distribution of insecticide treated nets on the island of Bioko, Equatorial Guinea, between 2004 and 2008 resulted in 95% effective coverage of children younger than five-years old, reduced infection prevalence from 42% to 18% and resulted in a reduction in under-five all-cause mortality from 157 to 55 per 1,000 live births [63].

The immediacy of the impact, the effect size and evidence of rebound following cessation of control, all suggest that the reductions seen in overall mortality must be explained by the reductions in parasite exposure and

that these reductions are greater than can be explained through a reduction in malaria-specific mortality alone.

The indirect consequences of malaria infection may be mediated through a number of mechanisms [64]. These include the insidious effects of chronic or repeated infection that lead to increased risks of severe anemia in pregnant women and children, growth retardation of fetuses and low-birth weight newborns [27,65,66]. There is also compelling evidence of the role played by *P. falciparum* infection in increasing the risks of invasive bacterial disease, most notably non-typhoidal Salmonellae [67-69]. When malaria transmission dramatically declined over ten years on the Kenyan coast the incidence of life-threatening gram-negative bacteremia was halved [70], confirming that this was directly related to malaria transmission. Further, there appears to be a protective effect of sickle cell trait against invasive bacterial disease, of the same order as its protection against malaria [70].

What can we measure?

The indirect impact of malaria infection may exceed any direct mortality outcomes, even if the latter could be measured. All-cause mortality is a definable endpoint and it has been argued that one should view malaria infection as a risk factor for survival, in similar ways to how under nutrition is treated as a risk [71]. This is important because it leads us onto what malaria quantity can be measured.

The complex direct and indirect public health burden posed by malaria in Africa is predominantly caused by a single pathogen, *P. falciparum*. Other high burden diseases are usually measured from routine survey data on the prevalence and incidence of the pathogen. Unlike HIV, the direct relationship between malaria infection and disease outcomes is complicated by genetically regulated, naturally acquired exposure-dependent immunity and less well understood variations in parasite virulence. As with all diagnostics for most pathogens, there are margins of error in being able to detect malaria parasites in the peripheral blood of infected hosts [72]. But infection can be measured with a much higher degree of certainty, more rapidly and more ubiquitously than the symptomatic consequences of infection based on a constellation of common childhood symptoms.

In Boyd's manual on malariology it states that '*It is inexcusable to initiate control activities in any community without a prior survey to determine ... the endemic level at which malaria is prevailing, and the extent of its localization...*' [13]. During the GMPE era the prevalence of the malaria parasite in a community was viewed as a reliable index of risk that would define how interventions were spatially targeted, and progress measured [73-75]. National surveys were undertaken in thousands of villages across Africa as part of 'pre-eradication' reconnaissance.

During experimental stages of elimination, parasite 'incidence' among infants born during periods of intervention was used to measure the immediacy of control impact [76].

There has been a renaissance in measuring infection prevalence during national sample household malaria indicator surveys since 2005. These more recent national surveys are poor substitutes for those designed and undertaken during the 1950s and 1960s. Current national malaria parasite prevalence surveys often cover fewer than 20 children younger than five years of age per sampled cluster and rarely consider infection prevalence among the entire community or provide information on multiple parasite or life-cycle stages of detected infections. Nevertheless, when combined with other available survey data, notably the revival of school-based measures of malaria risk [77], these data provide a unique opportunity to interpolate infection risks across space and time. The ubiquity and comparative sensitivity of parasite prevalence as a metric of risk has made it possible, for the first time, to measure changes in parasite exposure across Africa based on 26,746 surveys at 21,341 locations [78].

It has long been recognized that when transmission becomes less intense and unstable, there is a closer association between infection prevalence and disease. Disease is theoretically easier to measure without the confounding influence of immunity [79]. Conversely, under conditions of regular parasite exposure disease is much harder to define and the amount of malaria in a community is better measured by the prevalence of the parasite during a cross-sectional survey [79]. The level of transmission one needs to consider when measuring disease or infection is not clear [80]; however, if one assumes that when prevalence is more than 5% disease is hard to measure, then this currently covers 519 million people living in 41 countries of sub-Saharan Africa [78].

Conclusions

Are we any less ignorant of malaria's role in the health of communities in Africa since SP James visited East Africa in 1929? We know much more now on the protective role of acquired immunity, the clinical presentations and pathology of malaria as a disease, how disease phenotypes and age-patterns vary according to the intensity of transmission, the diversity of parasite exposure across the continent and the indirect consequences of malaria infection on health.

Multilateral agencies continue to demand actual numbers of a disease intrinsically hard to define, tending to focus on the point median estimates and ignoring the confidence interval. People often argue that some numbers are better than none. Sixty years ago this was probably a fair position; 15 to 20 years ago this might have been legitimate at a time when a case needed to be made

to highlight the 40 year neglect of malaria and its threat to global development. At the launch of the GMPEP and the more recent Roll Back Malaria (RBM) initiatives, numbers have been useful advocacy tools.

In the absence of reliable civil and health registration systems across a large part of stable endemic sub-Saharan Africa there are two things we can measure: whether someone has died (Millennium Development Goal 4) and whether someone is infected with the malaria parasite (not included in any development goals). The former encompasses the complex array of all risks posed by infection with malaria parasites; the latter is the etiological risk factor for premature mortality. Both are measurable with an acceptable degree of certainty. Yet it remains impossible to provide a single figure of the number of deaths or clinical events resulting from *P. falciparum* infection; or more importantly, how many of these events have been averted since the launch of unprecedented overseas development assistance since 2000.

It is a tragedy that, despite billions of health dollars spent on the control of malaria in Africa since 2000, we remain so uncertain about the health impact of this funding in 2014. Among countries at the margins of stable transmission in Africa, malaria elimination is now viewed, once again, as possible. In these areas, most infections will lead to an important disease outcome unaffected by acquired immunity and countries will require a sophisticated system of disease surveillance to track progress toward the ambitious target of no new clinical events. However, the majority of Africa's public health burden caused by *P. falciparum* does not occur at the margins but in the middle belt of sub-Saharan Africa where intense transmission leads to immunity within the first few years of life and the unique distinction of a malaria disease event is much harder to define. Investing now in longitudinal, more traditional, epidemiological metrics of malaria including species-specific infection prevalence, mosquito vector species abundance, bionomics and infectivity, accompanied by carefully assembled, quality assured clinical data from hospitals will provide public health specialists an opportunity to examine the success of continued investment in current control tools. Relying upon models based on inadequate, incomplete data of poorly defined disease outcomes should no longer be acceptable.

Competing interests

The author declares that he has no competing interests.

Acknowledgements

We are grateful for discussions and earlier comments on a draft of this paper from Abdulsalaan Mohamed Noor, Mike English, Abdinasir Amin, Alistair Robb and Philip Bejon. RWS is supported by the Wellcome Trust as Principal Research Fellow (# 079080 & # 103602). The views expressed in this paper do not reflect those of the funders.

Received: 17 September 2014 Accepted: 5 November 2014
Published online: 12 December 2014

References

1. James SP: *Report on a Visit to Kenya and Uganda to Advice on Antimalarial Measures*. London: Crown Agents for the Colonies; 1929:48.
2. Barber MA, Olinger MT: **Studies on malaria in Southern Nigeria**. *Ann Trop Med Parasitol* 1931, **25**:461–501.
3. Bruce-Chwatt LJ: **Malaria in Nigeria**. *Bull World Health Organ* 1951, **4**:301–327.
4. Bruce-Chwatt LJ: **Malaria in African infants and children in Southern Nigeria**. *Ann Trop Med Parasitol* 1952, **46**:173–200.
5. Miller MJ: **Observations on the natural history of malaria in the semi-resistant West African**. *Trans R Soc Trop Med Hyg* 1958, **52**:152–168.
6. Colbourne MJ: **Malaria in infancy**. *Cent Afr J Med* 1959, **5**:65–69.
7. Colbourne MJ, Edington GM: **Mortality from malaria in Accra**. *J Trop Med Hyg* 1954, **57**:203–210.
8. Duren AN: **Un essai d'étude d'ensemble du paludisme au Congo Belge**. *Inst Roy Colonial Sc Nat Médi Mém* 1937, **5**:26–51.
9. Kivits M: *Pathologie et Mortalité de l'enfance indigène au Mayumbe*, 19. Bruxelles: Institut Royal colonial belge. Sect. des sciences nat. et méd. Mémoires. Coll. in-8"; 1951:33.
10. Garnham PCC: **Hyperendemic malaria in a native reserve of Kenya and the influence upon its course of atebirin and plasmoquine**. *Trans R Soc Trop Med Hyg* 1935, **29**:167–186.
11. Garnham PC: **Malarial immunity in Africans: effects in infancy and early childhood**. *Ann Trop Med Parasitol* 1949, **43**:47–61.
12. Wilson DB: **Rural hyper-endemic malaria in Tanganyika territory**. *Trans R Soc Trop Med Hyg* 1936, **29**:583–618.
13. Wilson DB: **Implications of malarial endemicity in East Africa**. *Trans R Soc Trop Med Hyg* 1939, **32**:435–465.
14. Boyd MF: *Malariaology. A Comprehensive Survey of all Aspects of This Groups of Diseases from a Global Perspective, Volume 2*. WB Saunders Co: Philadelphia and London; 1949.
15. Greenwood BM, Marsh K, Snow RW: **Why do some children develop severe malaria?** *Parasitol Today* 1991, **7**:277–281.
16. Greenwood BM: **Populations at risk**. *Parasitol Today* 1990, **6**:188.
17. Sturchler D: **How much malaria is there worldwide?** *Parasitol Today* 1989, **5**:39–40.
18. Snow RW, Amratia P, Kabaria CW, Noor AM, Marsh K: **The changing limits and incidence of malaria in Africa: 1939–2009**. *Adv Parasitol* 2012, **78**:169–262.
19. Nabarro D, Taylor EM: **The roll back malaria campaign**. *Science* 1998, **280**:2067–2068.
20. Murray CJ, Lopez AD: **Mortality by cause for eight regions of the world: Global Burden of Disease Study**. *Lancet* 1997, **349**:1269–1276.
21. Snow RW, Craig MH, Deichmann U, Marsh K: **Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population**. *Bull World Health Organ* 1999, **77**:624–640.
22. Korenromp E, Williams BG, Gouws E, Dye C, Snow RW: **Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy**. *Lancet Infect Dis* 2003, **3**:349–358.
23. Korenromp EL, Roll Back Malaria Monitoring and Evaluation Reference Group and MERG Task Force on Malaria Morbidity: *Malaria Incidence Estimates at Country Level for the Year 2004 – Proposed Estimates and Draft Report, Roll Back Malaria*. Geneva: World Health Organization; 2004. http://www.who.int/malaria/publications/atoz/incidence_estimations2.pdf.
24. Snow RW, Craig M, Newton C, Steketee RW: *The Public Health Burden of Plasmodium Falciparum Malaria in Africa: Deriving the Numbers*. Washington DC: The Disease Control Priorities Project (DCPP) Working Paper Number 11; 2003. http://archives.who.int/prioritymeds/report/append/610snow_wp11.pdf.
25. Snow RW, Guerra GA, Noor AM, Myint HL, Hay SI: **The global distribution of clinical episodes of Plasmodium falciparum malaria**. *Nature* 2005, **434**:214–217.
26. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Armstrong Schellenberg JRM, Stein C, Nahlen B, Bryce J, Black RE, Steketee RW: **The burden of malaria mortality among African children in the year 2000**. *Int J Epidemiol* 2006, **35**:691–704.
27. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoah K, Brabin B, Newman R: **Epidemiology and burden of malaria in pregnancy**. *Lancet Infect Dis* 2007, **7**:93–104.
28. Roca-Feltrer A, Carneiro I, Armstrong Schellenberg JR: **Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years**. *Trop Med Int Health* 2008, **13**:771–783.
29. World Health Organization: *The World Malaria Report 2008*; 2008. <http://www.who.int/malaria/publications/atoz/9789241563697/en/>.
30. Hay SI, Okiro EA, Patil AP, Gething PW, Guerra CA, Tatem AJ, Snow RW: **Estimating the global clinical burden of Plasmodium falciparum malaria in 2007**. *PLoS Med* 2010, **7**:e1000290.
31. Eisele TP, Larsen D, Walker N, Steketee RW, Cibulskis RE: *Saving Lives with Malaria Control: Counting Down to the Millennium Development Goals, RBM Progress & Impact Series no. 3*. Geneva: World Health Organization; 2010.
32. Eisele TP, Larsen DA, Walker N, Cibulskis RE, Yukich JO, Zikusooka CM, Steketee RW: **Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001–2010**. *Malar J* 2012, **11**:93.
33. Komatsu R, Korenromp EL, Low-Beer D, Watt C, Dye C, Steketee RW, Nahlen BL, Lyerla R, Garcia-Calleja JM, Cutler J, Schwartländer B: **Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007**. *BMC Infect Dis* 2010, **10**:109.
34. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C, Child Health Epidemiology Reference Group of WHO and UNICEF: **Global, regional, and national causes of child mortality in 2008: a systematic analysis**. *Lancet* 2010, **375**:1969–1987.
35. World Health Organization: *The World Malaria Report 2011*. 2011. http://www.who.int/malaria/world_malaria_report_2011/en/.
36. Cibulskis RE, Aregawi M, Williams R, Otten M, Dye C: **Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods**. *PLoS Med* 2011, **8**:e1001142.
37. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD: **Global malaria mortality between 1980 and 2010: a systematic analysis**. *Lancet* 2012, **379**:413–431.
38. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health Epidemiology Reference Group of WHO and UNICEF: **Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000**. *Lancet* 2012, **379**:2151–2161.
39. Cairns M, Roca-Feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, Ghani AC, Greenwood BM: **Estimating the potential public health impact of seasonal malaria chemoprevention in African children**. *Nat Commun* 2012, **3**:881.
40. Griffin JT, Ferguson NM, Ghani AC: **Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa**. *Nat Commun* 2014, **5**:3136.
41. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, Wang H, Duber HC, Naghavi M, Dicker D, Dandona L, Salomon JA, Heuton KR, Foreman K, Phillips DE, Fleming TD, Flaxman AD, Phillips BK, Johnson EK, Coggeshall MS, Abd-Allah F, Abera SF, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, et al: **Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013**. *Lancet* 2014, **384**:1005–1070.
42. Anker M, Black RE, Coldham C, Kalter HD, Quigley MA, Ross D, Snow RW: *A Standard Verbal Autopsy Method for Investigating Causes of Death in Infants and Children*. Geneva: World Health Organization; 1999.
43. Byass P, de Courten M, Graham WJ, Laflamme L, McCaw-Binns A, Sankoh OA, Tollman SM, Zaba B: **Reflections on the global burden of disease 2010 estimates**. *PLoS Med* 2013, **10**:e1001477.
44. Trape JF, Peelman P, Morault-Peelmann B: **Criteria for diagnosing clinical malaria among a semi-immune population exposed to intense and perennial transmission**. *Trans R Soc Trop Med Hyg* 1985, **79**:435–442.
45. Rougemont A, Breslow N, Brenner E, Moret AL, Dumbo O, Dolo A, Soula G, Penn L: **Epidemiological basis for clinical diagnosis of childhood malaria in endemic zone in West Africa**. *Lancet* 1991, **338**:1292–1295.
46. Armstrong-Schellenberg JR, Smith T, Alonso PL, Hayes R: **What is clinical malaria? Finding case definitions for field research in highly endemic areas**. *Parasitol Today* 1994, **10**:439–442.
47. Rogier C, Commenges D, Trape JF: **Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations**. *Am J Trop Med Hyg* 1996, **54**:613–619.

48. Dicko A, Mantel C, Kouriba B, Sagara I, Thera MA, Doumbia S, Diallo M, Poudiougou B, Diakite M, Doumbo OK: **Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali.** *Trop Med Int Health* 2005, **10**:550–556.
49. Mwangi TW, Mohammed M, Dayo H, Snow RW, Marsh K: **Clinical algorithms for malaria diagnosis lack utility among people of different age groups.** *Trop Med Int Health* 2005, **10**:530–536.
50. Mwangi TW, Ross A, Snow RW, Marsh K: **Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya.** *J Infect Dis* 2005, **191**:1932–1939.
51. Tiono AB, Kangoye DT, Rehman AM, Kargougou DG, Kabore' Y, Diarra A, Ouedraogo E, Nébié I, Ouedraogo A, Okech B, Milligan P, Sirima SB, Sirima SB: **Malaria incidence in children in South-West Burkina Faso: Comparison of active and passive case detection methods.** *PLoS One* 2014, **9**:e86936.
52. Snow RW, Menon A, Greenwood BM: **Measuring morbidity from malaria.** *Ann Trop Med Parasitol* 1989, **83**:321–323.
53. Coleman PG, Pery BD, Woolhouse ME: **Endemic stability - a veterinary idea applied to human public health.** *Lancet* 2001, **357**:1284–1286.
54. Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta S, Marsh K: **Relation between severe malaria morbidity in children and level of *Plasmodium falciparum* transmission in Africa.** *Lancet* 1997, **349**:1650–1654.
55. Snow RW, Marsh K: **The consequences of reducing *Plasmodium falciparum* transmission in Africa.** *Adv Parasitol* 2002, **52**:235–264.
56. Smith T, Killeen G, Lengeler C, Tanner M: **Relationships between the outcome of *Plasmodium falciparum* infection and the intensity of transmission in Africa.** *Am J Trop Med Hyg* 2004, **71**:80–86.
57. Lynch M, Korenromp E, Eisele T, Newby H, Steketee R, Kachur SP, Nahlen B, Bhattarai A, Yoon S, MacArthur J, Newman R, Cibulskis R: **New global estimates of malaria deaths.** *Lancet* 2012, **380**:559.
58. Programme NMC: *Ministry of Health: Swaziland National Malaria Indicator Survey 2010.* Kingdom of Swaziland: National Malaria Control Programme, Ministry of Health; 2011.
59. Churcher TS, Cohen JM, Novotny J, Ntshalintshali N, Kunene S, Cauchemez S: **Measuring the path toward malaria elimination: Developing new targets and milestones from standard surveillance data.** *Science* 2014, **344**:1230–1232.
60. Smith A, Draper CC: **Malaria in the Taveta area of Kenya and Tanganyika. Part II. Results after three and a half years' treatment of huts with dieldrin.** *East Afr Med J* 1959, **36**:629–643.
61. Draper CC, Smith A: **Malaria in the Pare area of Tanganyika. Part II. Effects of three years' spraying of huts with dieldrin.** *Trans R Soc Trop Med Hyg* 1960, **54**:342–357.
62. Payne D, Grab R, Fontaine RE, Hempel JH: **Impact of control measures on malaria transmission and general mortality.** *Bull World Health Organ* 1976, **54**:369–377.
63. Kleinschmidt I, Schwabe C, Benavente L, Torrez M, Ridl FC, Segura JL, Ehmer P, Nchama GN: **Marked increase in child survival after four years of intensive malaria control.** *Am J Trop Med Hyg* 2009, **80**:882–888.
64. Molineaux L: **Malaria and mortality: some epidemiological considerations.** *Ann Trop Med Parasitol* 1997, **91**:811–825.
65. Guyatt HL, Snow RW: **Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa.** *Trans R Soc Trop Med Hyg* 2001, **95**:569–576.
66. Guyatt HL, Snow RW: **Impact of malaria during pregnancy on low birth weight in Sub-Saharan Africa.** *Clin Microbiol Rev* 2004, **17**:760–769.
67. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, Ngetsa C, Slack MP, Njenga S, Hart CA, Maitland K, English M, Marsh K, Scott JA: **Bacteremia among children admitted to a rural hospital in Kenya.** *N Engl J Med* 2005, **352**:39–47.
68. Church J, Maitland K: **Invasive bacterial co-infection in African children with *Plasmodium falciparum* malaria: a systematic review.** *BMC Med* 2014, **12**:31.
69. Mackenzie G, Ceesay SJ, Hill PC, Walther M, Bojang KA, Satoguina J, Enwere G, D'Alessandro U, Saha D, Ikumapayi UN, O' Dempsey T, Mabey DC, Corrah T, Conway DJ, Adegbola RA, Greenwood BM, Greenwood BM: **A decline in the incidence of invasive non-typhoidal salmonella infection in The Gambia temporally associated with a decline in malaria infection.** *PLoS One* 2010, **5**:e10568.
70. Scott JA, Berkley JA, Mwangi I, Ochola L, Uyoga S, Macharia A, Ndila C, Lowe BS, Mwarumba S, Bauni E, Marsh K, Williams TN: **Relation between *falciparum* malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.** *Lancet* 2011, **378**:1316–1323.
71. Snow RW, Korenromp EL, Gouws E: **Paediatric mortality in Africa: *Plasmodium falciparum* malaria as a cause or a risk?** *Am J Trop Med Hyg* 2004, **71**:16–24.
72. Okell LC, Ghani AC, Lyons E, Drakeley CJ: **Sub-microscopic infection in *Plasmodium falciparum* endemic populations: a systematic review and meta-analysis.** *J Infect Dis* 2009, **200**:1509–1517.
73. Macdonald G: *The Epidemiology and Control of Malaria.* Oxford University Press; 1957.
74. Pampana E: *A Textbook on Malaria Eradication.* Oxford University Press; 1969.
75. Pull JH: **Malaria surveillance methods, their uses and limitations.** *Am J Trop Med Hyg* 1972, **21**:651–657.
76. MacDonald G: **The analysis of malaria parasite rates in infants.** *Trop Dis Bull* 1950, **17**:915–938.
77. Brooker S, Kolaczinski JH, Gitonga CW, Noor AM, Snow RW: **The use of schools for malaria surveillance and programme evaluation in Africa.** *Malar J* 2009, **8**:231.
78. Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Wambua JM, Alegana VA, Fall IS, Snow RW: **The changing risk of *Plasmodium falciparum* malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity.** *Lancet* 2014, **383**:1739–1747.
79. Garnham PC: **Modern concepts in malaria control.** *J R Sanit Inst* 1949, **69**:617–625.
80. Yekutieli P: **Problems of epidemiology in malaria eradication.** *Bull World Health Organ* 1960, **22**:669–683.

doi:10.1186/s12916-014-0227-x

Cite this article as: Snow: Sixty years trying to define the malaria burden in Africa: have we made any progress? *BMC Medicine* 2014 **12**:227.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

